U012 “Bread n’ Butter with a Side of Nutella”: Short n’ Sweet, High-Yield Updates on Management of Bread n’ Butter Dermatologic Diseases
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session will focus on reviewing the newest evidence-based treatment(s) for common dermatologic diseases including, warts, itch, blistering diseases and psoriasis, as well as updates in dermatopathology in diagnosis of diseases such as melanoma. Practicing dermatologist often do not have time to keep up with the latest evidence in clinical management. This session includes five high-impact, high-yield, “short n’ sweet” updates in management of diseases that dermatologists most commonly encounter.
LEARNING OBJECTIVES
Summarize database and comparative effectiveness research on existing treatment(s) for common dermatologic diseases and specific disease phenotypes.
Summarize updates in new, existing and down-the-pipeline treatments for common dermatologic diseases.
Diagnose and determine treatment of common diseases using the newest technology in dermatopathology.
SCHEDULE
3:30 PM
High-Yield Pearls for Management of Warts with Therapeutic Updates
Jennifer Adams, MD, FAAD
3:42 PM
Updates on Treatment of Autoimmune Bullous Diseases
Erin Wei, MD, FAAD
3:54 PM
What’s New in the Treatment of Itch
Megan Arthur, MD, FAAD
4:06 PM
High-yield Pearls for Management of Psoriasis with Therapeutic Updates
Sarah Lonowski, MD, MBA, FAAD
4:18 PM
Updates in Dermatopathology that will Change Your Practice
Corey J Georgesen, MD, FAAD
SPEAKERS
Jennifer Adams, MD, FAAD
Megan Arthur, MD, FAAD
Corey J Georgesen, MD, FAAD
Sarah Lonowski, MD, MBA, FAAD
Erin Wei, MD, FAAD
SPEAKER DISCLOSURES
Jennifer Adams, MD, FAAD
L'Oreal – Advisory Board(Honoraria);
Megan Arthur, MD, FAAD
No financial relationships exist with ineligible companies.
Corey J Georgesen, MD, FAAD
No financial relationships exist with ineligible companies.
Sarah Lonowski, MD, MBA, FAAD
No financial relationships exist with ineligible companies.
Erin Wei, MD, FAAD
No financial relationships exist with ineligible companies.